Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model - role of tumor stroma cells

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Leithner, Katharina ^a   Wohlkoenig, Christoph ^a   Stacher, Elvira ^a   Lindenmann, Jörg ^a   Hofmann, Nicole A ^a   Gallé, Birgit ^a   Guelly, Christian ^a   Quehenberger, Franz ^a   Stiegler, Philipp ^a   Smolle Jüttner, Freyja Maria ^a   Philipsen, Sjaak ^b   Popper, Helmut H ^a   Hrzenjak, Andelko ^a,c   Olschewski, Andrea ^a,c   Olschewski, Horst ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Expression array; Hypoxia; Prognosis; Tumor

Indexed keywords

MEMBRANE METALLOENDOPEPTIDASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOMA ASSOCIATED FIBROBLAST; CELL VIABILITY; CONTROLLED STUDY; EX VIVO STUDY; FIBROBLAST; FIBROBLAST CULTURE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXEMIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MME GENE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; OXYGEN CONCENTRATION; STROMA CELL; UPREGULATION;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NEPRILYSIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STROMAL CELLS; TISSUE CULTURE TECHNIQUES; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84892727952     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-40     Document Type: Article

References (59)

1. Manegold C, Thatcher N. Survival improvement in thoracic cancer: progress from the last decade and beyond. Lung Cancer 2007, 57(Suppl 2):S3-S5.
2. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93(4):266-276. 10.1093/jnci/93.4.266, 11181773.
3. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010, 29(5):625-634. 10.1038/onc.2009.441, 2969168, 19946328.
4. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47. 10.1038/nrc704, 11902584.
5. Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 2011, 183(2):152-156. 10.1164/rccm.201009-1393PP, 3159088, 21242594.
6. Giaccia AJ, Schipani E. Role of carcinoma-associated fibroblasts and hypoxia in tumor progression. Curr Top Microbiol Immunol 2010, 345:31-45.
7. Schmid JO, Dong M, Haubeiss S, Friedel G, Bode S, Grabner A, Ott G, Murdter TE, Oren M, Aulitzky WE, van der Kuip H. Cancer cells Cue the p53 response of cancer-associated fibroblasts to cisplatin. Cancer Res 2012, 72(22):5824-5832. 10.1158/0008-5472.CAN-12-1201, 22962266.
8. Hougardy BM, Reesink-Peters N, van den Heuvel FA, ten Hoor KA, Hollema H, de Vries EG, de Jong S, van der Zee AG. A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants. Int J Cancer 2008, 123(6):1457-1465. 10.1002/ijc.23684, 18567003.
9. Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res 2004, 10(24):8697-8703. 10.1158/1078-0432.CCR-04-1166, 15623655.
10. Navab R, Strumpf D, Bandarchi B, Zhu CQ, Pintilie M, Ramnarine VR, Ibrahimov E, Radulovich N, Leung L, Barczyk M, Panchal D, To C, Yun JJ, Der S, Shepherd FA, Jurisica I, Tsao MS. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer. Proc Natl Acad Sci USA 2011, 108(17):7160-7165. 10.1073/pnas.1014506108, 3084093, 21474781.
11. Avcuoglu S, Wygrecka M, Marsh LM, Gunther A, Seeger W, Weissmann N, Fink L, Morty RE, Kwapiszewska G. Neurotrophic tyrosine kinase receptor B/neurotrophin 4 signaling axis is perturbed in clinical and experimental pulmonary fibrosis. Am J Respir Cell Mol Biol 2011, 45(4):768-780. 10.1165/rcmb.2010-0195OC, 21330466.
12. Michiels S, Baujat B, Mahe C, Sargent DJ, Pignon JP. Random effects survival models gave a better understanding of heterogeneity in individual patient data meta-analyses. J Clin Epidemiol 2005, 58(3):238-245. 10.1016/j.jclinepi.2004.08.013, 15718112.
13. Ripatti S, Palmgren J. Estimation of multivariate frailty models using penalized partial likelihood. Biometrics 2000, 56(4):1016-1022. 10.1111/j.0006-341X.2000.01016.x, 11129456.
14. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 2000, 157(2):411-421. 10.1016/S0002-9440(10)64554-3, 1850121, 10934146.
15. Andersen S, Eilertsen M, Donnem T, Al-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 2011, 72(3):294-302. 10.1016/j.lungcan.2010.10.006, 21075472.
16. Kleiter MM, Thrall DE, Malarkey DE, Ji X, Lee DY, Chou SC, Raleigh JA. A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103 F as a control hypoxia marker. Int J Radiat Oncol Biol Phys 2006, 64(2):592-602. 10.1016/j.ijrobp.2005.09.010, 16289910.
17. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006, 12(5):1507-1514. 10.1158/1078-0432.CCR-05-2049, 16533775.
18. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Clin Oncol 2006, 24(11):1679-1688. 10.1200/JCO.2005.03.8224, 16549822.
19. Tomida S, Takeuchi T, Shimada Y, Arima C, Matsuo K, Mitsudomi T, Yatabe Y, Takahashi T. Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. J Clin Oncol 2009, 27(17):2793-2799. 10.1200/JCO.2008.19.7053, 19414676.
20. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA, Tsao MS. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol 2010, 28(29):4417-4424. 10.1200/JCO.2009.26.4325, 2988634, 20823422.
21. Hou J, Aerts J, den Hamer B, van Ijcken W, den Bakker M, Riegman P, van der Leest C, van der Spek P, Foekens JA, Hoogsteden HC, Grosveld F, Philipsen S. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS One 2010, 5(4):e10312. 10.1371/journal.pone.0010312, 2858668, 20421987.
22. Lisanti MP, Martinez-Outschoorn UE, Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A, Witkiewicz A, Lin Z, Balliet R, Howell A, Sotgia F. Understanding the " lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment. Cancer Biol Ther 2010, 10(6):537-542. 10.4161/cbt.10.6.13370, 3040943, 20861671.
23. Loboda A, Jozkowicz A, Dulak J. HIF-1 versus HIF-2-is one more important than the other?. Vascul Pharmacol 2012, 56(5-6):245-251.
24. Wohlkoenig C, Leithner K, Deutsch A, Hrzenjak A, Olschewski A, Olschewski H. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells. Cancer Lett 2011, 308(2):134-143. 10.1016/j.canlet.2011.03.014, 21669489.
25. Ortiz-Barahona A, Villar D, Pescador N, Amigo J, del Peso L. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res 2010, 38(7):2332-2345. 10.1093/nar/gkp1205, 2853119, 20061373.
26. Buffa FM, Harris AL, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010, 102(2):428-435. 10.1038/sj.bjc.6605450, 2816644, 20087356.
27. Koritzinsky M, Seigneuric R, Magagnin MG, van den Beucken T, Lambin P, Wouters BG. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol 2005, 76(2):177-186. 10.1016/j.radonc.2005.06.036, 16098621.
28. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ. Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem 2009, 284(25):16767-16775. 10.1074/jbc.M901790200, 2719312, 19386601.
29. Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin N, Sloan P, Price P, West CM, Harris AL. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007, 67(7):3441-3449. 10.1158/0008-5472.CAN-06-3322, 17409455.
30. Loewen N, Chen J, Dudley VJ, Sarthy VP, Mathura JR. Genomic response of hypoxic Müller cells involves the very low density lipoprotein receptor as part of an angiogenic network. Exp Eye Res 2009, 88(5):928-937. 10.1016/j.exer.2008.11.037, 19233325.
31. Costello CM, Howell K, Cahill E, McBryan J, Konigshoff M, Eickelberg O, Gaine S, Martin F, McLoughlin P. Lung-selective gene responses to alveolar hypoxia: potential role for the bone morphogenetic antagonist gremlin in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2008, 295(2):L272-L284. 10.1152/ajplung.00358.2007, 18469115.
32. Koklanaris N, Nwachukwu JC, Huang SJ, Guller S, Karpisheva K, Garabedian M, Lee MJ. First-trimester trophoblast cell model gene response to hypoxia. Am J Obstet Gynecol 2006, 194(3):687-693. 10.1016/j.ajog.2006.01.067, 16522398.
33. Shen GM, Zhang FL, Liu XL, Zhang JW. Hypoxia-inducible factor 1-mediated regulation of PPP1R3C promotes glycogen accumulation in human MCF-7 cells under hypoxia. FEBS Lett 2010, 584(20):4366-4372. 10.1016/j.febslet.2010.09.040, 20888814.
34. Fisk L, Nalivaeva NN, Boyle JP, Peers CS, Turner AJ. Effects of hypoxia and oxidative stress on expression of neprilysin in human neuroblastoma cells and rat cortical neurones and astrocytes. Neurochem Res 2007, 32(10):1741-1748. 10.1007/s11064-007-9349-2, 17486446.
35. Wick MJ, Buesing EJ, Wehling CA, Loomis ZL, Cool CD, Zamora MR, Miller YE, Colgan SP, Hersh LB, Voelkel NF, Dempsey EC. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011, 183(3):330-340. 10.1164/rccm.201002-0154OC, 3056229, 20813891.
36. Wang Z, Yang D, Zhang X, Li T, Li J, Tang Y, Le W. Hypoxia-induced down-regulation of neprilysin by histone modification in mouse primary cortical and hippocampal neurons. PLoS One 2011, 6(4):e19229. 10.1371/journal.pone.0019229, 3084787, 21559427.
37. Mitra R, Chao OS, Nanus DM, Goodman OB. Negative regulation of NEP expression by hypoxia. Prostate 2013, 73(7):706-714. 10.1002/pros.22613, 23138928.
38. Dempsey EC, Wick MJ, Karoor V, Barr EJ, Tallman DW, Wehling CA, Walchak SJ, Laudi S, Le M, Oka M, Majka S, Cool CD, Fagan KA, Klemm DJ, Hersh LB, Gerard NP, Gerard C, Miller YE. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Pathol 2009, 174(3):782-796. 10.2353/ajpath.2009.080345, 2665740, 19234135.
39. Carpenter TC, Stenmark KR. Hypoxia decreases lung neprilysin expression and increases pulmonary vascular leak. Am J Physiol Lung Cell Mol Physiol 2001, 281(4):L941-L948.
40. Gurel D, Kargi A, Karaman I, Onen A, Unlu M. CD10 expression in epithelial and stromal cells of non-small cell lung carcinoma (NSCLC): a clinic and pathologic correlation. Pathol Oncol Res 2012, 18(2):153-160. 10.1007/s12253-011-9421-8, 21681600.
41. Ono S, Ishii G, Nagai K, Takuwa T, Yoshida J, Nishimura M, Hishida T, Aokage K, Fujii S, Ikeda N, Ochiai A. Podoplanin-positive cancer-associated fibroblasts could have prognostic value independent of cancer cell phenotype in stage I lung squamous cell carcinoma: usefulness of combining analysis of both cancer cell phenotype and cancer-associated fibroblast phenotype. Chest 2013, 143(4):963-970. 10.1378/chest.12-0913, 23081722.
42. Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 2011, 6(1):209-217. 10.1097/JTO.0b013e3181f8a1bd, 21107292.
43. Ishimaru F, Shipp MA. Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements. Blood 1995, 85(11):3199-3207.
44. de Launoit Y, Baert JL, Chotteau-Lelievre A, Monte D, Coutte L, Mauen S, Firlej V, Degerny C, Verreman K. The Ets transcription factors of the PEA3 group: transcriptional regulators in metastasis. Biochim Biophys Acta 2006, 1766(1):79-87.
45. Wollenick K, Hu J, Kristiansen G, Schraml P, Rehrauer H, Berchner-Pfannschmidt U, Fandrey J, Wenger RH, Stiehl DP. Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling. Nucleic Acids Res 2012, 40(5):1928-1943. 10.1093/nar/gkr978, 3300025, 22075993.
46. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta 2005, 1751(1):52-59. 10.1016/j.bbapap.2004.11.001, 16054017.
47. Maguer-Satta V, Besancon R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells 2011, 29(3):389-396. 10.1002/stem.592, 21425402.
48. Morisaki N, Moriwaki S, Sugiyama-Nakagiri Y, Haketa K, Takema Y, Imokawa G. Neprilysin is identical to skin fibroblast elastase: its role in skin aging and UV responses. J Biol Chem 2010, 285(51):39819-39827. 10.1074/jbc.M110.161547, 3000963, 20876573.
49. Mazurov D, Barbashova L, Filatov A. Tetraspanin protein CD9 interacts with metalloprotease CD10 and enhances its release via exosomes. FEBS J 2013, 280(5):1200-1213. 10.1111/febs.12110, 23289620.
50. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, Kodama K, Tachibana S, Sasaki S, Miyake M. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001, 49(8):489-496. 10.1007/BF02919543, 11552274.
51. Kristiansen G, Schlüns K, Yongwei Y, Dietel M, Petersen I. CD10 expression in non-small cell lung cancer. Anal Cell Pathol 2002, 24(1):41-46.
52. Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE. Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux. Cancer Res 1996, 56(4):831-839.
53. Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Stein H, Sunday ME, Reinherz EL. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci USA 1991, 88(23):10662-10666. 10.1073/pnas.88.23.10662, 52990, 1660144.
54. Bunn PA, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res 1998, 4(11):2849-2858.
55. Wright JL, Jeng AY, Battistini B. Effect of ECE and NEP inhibition on cigarette smoke-induced cell proliferation in the rat lung. Inhal Toxicol 2001, 13(6):497-511.
56. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449(7162):557-563. 10.1038/nature06188, 17914389.
57. Cui L, Ohuchida K, Mizumoto K, Moriyama T, Onimaru M, Nakata K, Nabae T, Ueki T, Sato N, Tominaga Y, Tanaka M. Prospectively isolated cancer-associated CD10(+) fibroblasts have stronger interactions with CD133(+) colon cancer cells than with CD133(-) cancer cells. PLoS One 2010, 5(8):e12121. 10.1371/journal.pone.0012121, 2920818, 20711432.
58. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 2008, 14(22):7430-7437. 10.1158/1078-0432.CCR-08-0935, 19010860.
59. Katsuda T, Tsuchiya R, Kosaka N, Yoshioka Y, Takagaki K, Oki K, Takeshita F, Sakai Y, Kuroda M, Ochiya T. Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci Rep 2013, 3:1197. 3561625, 23378928.